Head and Neck Cancer Trial, Recruiting NCT06686342 Sponsor: Huashan Hospital Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Head and Neck Cancer Trial, Recruiting

NCT06686342
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with recurrent or metastatic head and neck squamous cell carcinoma (a specific type of head and neck cancer), confirmed by laboratory testing
  • People who have tumor tissue available that can be used to grow cancer cell cultures for the study
  • People whose general physical functioning is reasonably well-maintained (as measured by a standard performance scale, scored 0–2)
  • People whose doctors estimate they have a life expectancy of more than 3 months
  • People whose major organs (blood, liver, kidneys, and clotting system) are functioning within specific healthy ranges, as shown by blood tests, meaning the body is considered able to tolerate chemotherapy, targeted therapy, and immunotherapy
  • People who are able to understand the study information, sign a consent form, and are willing to attend follow-up appointments

Who may not be able to join:

  • People whose head and neck cancer has spread from another part of the body, or whose cancer is a different type (such as sarcoma, adenocarcinoma, or nasopharyngeal carcinoma) rather than squamous cell carcinoma
  • People who are known to be allergic to the study drugs, their ingredients, or who have had a severe allergic reaction to other monoclonal antibody treatments in the past
  • People who are pregnant or breastfeeding, or people of childbearing potential who test positive for pregnancy within 7 days before enrolment, or who test negative but are unwilling to use effective contraception during the study and for 2 months after the last dose; this also applies to male participants with partners who could become pregnant, if they are unwilling to use effective contraception during the same period
  • People with severe liver disease (such as cirrhosis), kidney disease, respiratory disease, blood disorders, or uncontrolled endocrine (hormonal) conditions
  • People living with HIV, active hepatitis B, or active hepatitis C that is not controlled
  • People who have had a heart attack, severe chest pain, significant heart failure, serious heart rhythm problems, or uncontrolled heart failure within the 6 months before enrolling
  • People with a mental illness, or a known history of psychiatric medication misuse or drug addiction
  • People who are unable to give informed consent, or from whom the required amount of tumour tissue cannot be obtained
  • People with other serious physical or mental health conditions, abnormal lab results, or any other circumstances that the research team considers would make participation unsuitable or risky

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Lai-ping Zhong, MD, PhD, Huashan Hospital

Phone: +862152888915

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Huashan Hospital
Registry
ClinicalTrials.gov
Start date
26 March 2025
Est. completion
11 November 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Objective Response Rate; Disease Control Rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov